Single-Step Universal First-Trimester Cytomegalovirus Screening and Valacyclovir Prophylaxis in Pregnancy: A Cost-Utility Analysis in a High Seroprevalence Setting.

ABSTRACT:

Objective

To evaluate the cost-effectiveness of first trimester single-step universal cytomegalovirus (CMV) serological screening with valacyclovir as vertical transmission prophylaxis versus routine ultrasound-directed testing.

Methods

A payer perspective cost-utility analysis was conducted on a hypothetical population of 100,000 pregnant women for a time horizon of 9 month of full-term pregnancy and the lifetime of children. Using a decision-tree and Markov model, we assessed quality-adjusted life years (QALYs) gained by preventing congenital CMV (cCMV) sequelae against the costs of universal screening and valacyclovir prophylaxis.

Results

The ICER for universal screening strategy was USD125,864 (SGD170,087)/QALY-gained compared to routine ultrasound-directed testin

SUBMITTER: Lim ZZ 

PROVIDER: S-EPMC12442333 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature